As the production of TCF1+ stem-like CD8+ T cells is related to protective immunity following cancer vaccination [16], the prognosis of the patient [12], and putative future memory T cells [27], we evaluated whether stem-like CD8+ T cells were increased by mJX-594 treatment. The gene discussed is CD8A; the disease is cancer.